Business Context and Reporting Period
Company: Bone Biologics Corp (Emerging Growth Company)
Filing Type: Form 8-K (Current Report)
Date of Report: March 26, 2018 (Event Date)
Reporting Period: Specific event date; not a periodic financial report.
Key Financial Metrics and Transaction Details
This filing reports a specific equity financing transaction rather than periodic financial performance metrics (revenue, profit, cash flow, or margins are not disclosed in this document).
- Investor: Orthofix Holdings, Inc.
- Instrument: 250,000 restricted shares of Common Stock.
- Price per Share: $2.00.
- Total Proceeds: $500,000 (calculated from 250,000 shares x $2.00).
- Registration Rights: Shares are subject to demand registration rights.
- Legal Basis: Issued under Section 4(a)(2) of the Securities Act of 1933 (private placement to accredited investor).
Material Changes Versus Prior Period
The filing does not provide comparative financial data or year-over-year changes. The material change reported is the entry into a definitive subscription agreement and the subsequent issuance of unregistered equity securities.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release issued on March 29, 2018, regarding the financing but does not include specific forward-looking guidance or operational outlook within the text of this 8-K.
Risks and Contingencies: The transaction relies on the investor's status as an accredited investor and the absence of a public offering. No specific operational risks are detailed in this excerpt.
Key Facts for Investor Verification
- Verify the full terms of the Subscription Agreement (Exhibit 10.1) for any additional covenants or restrictions beyond demand registration rights.
- Confirm the use of proceeds from the $500,000 financing in the referenced March 29, 2018 press release (Exhibit 99.1).
- Check subsequent filings to determine if the demand registration rights were exercised or if the shares were registered for public trading.
- Review the company's most recent 10-K or 10-Q for baseline financial health, as this 8-K contains no balance sheet or income statement data.